Literature DB >> 22762550

Lack of JAK2 activating non-synonymous mutations in diffuse large B-cell tumors: JAK2 deregulation still unexplained.

Thomas E Witzig, Tammy L Price-Troska, Mary J Stenson, Mamta Gupta.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22762550      PMCID： PMC3951413          DOI： 10.3109/10428194.2012.708931

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  17 in total

1.  SOCS1 and SHP1 hypermethylation in mantle cell lymphoma and follicular lymphoma: implications for epigenetic activation of the Jak/STAT pathway.

Authors:  C S Chim; K Y Wong; F Loong; G Srivastava
Journal:  Leukemia       Date:  2004-02       Impact factor: 11.528

2.  Absence of the JAK2 V617F activating mutation in classical Hodgkin lymphoma and primary mediastinal B-cell lymphoma.

Authors:  I Melzner; M A Weniger; C K Menz; P Möller
Journal:  Leukemia       Date:  2006-01       Impact factor: 11.528

3.  Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas.

Authors:  B Belinda Ding; J Jessica Yu; Raymond Y-L Yu; Lourdes M Mendez; Rita Shaknovich; Yonghui Zhang; Giorgio Cattoretti; B Hilda Ye
Journal:  Blood       Date:  2007-10-19       Impact factor: 22.113

4.  The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia.

Authors:  Ross L Levine; Marc Loriaux; Brian J P Huntly; Mignon L Loh; Miroslav Beran; Eric Stoffregen; Roland Berger; Jennifer J Clark; Stephanie G Willis; Kim T Nguyen; Nikki J Flores; Elihu Estey; Norbert Gattermann; Scott Armstrong; A Thomas Look; James D Griffin; Olivier A Bernard; Michael C Heinrich; D Gary Gilliland; Brian Druker; Michael W N Deininger
Journal:  Blood       Date:  2005-08-04       Impact factor: 22.113

5.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.

Authors:  Chloé James; Valérie Ugo; Jean-Pierre Le Couédic; Judith Staerk; François Delhommeau; Catherine Lacout; Loïc Garçon; Hana Raslova; Roland Berger; Annelise Bennaceur-Griscelli; Jean Luc Villeval; Stefan N Constantinescu; Nicole Casadevall; William Vainchenker
Journal:  Nature       Date:  2005-04-28       Impact factor: 49.962

6.  STAT3 is constitutively activated in Hodgkin cell lines.

Authors:  D Kube; U Holtick; M Vockerodt; T Ahmadi; B Haier; I Behrmann; P C Heinrich; V Diehl; H Tesch
Journal:  Blood       Date:  2001-08-01       Impact factor: 22.113

7.  Analysis of BRAF mutation in primary and metastatic melanoma.

Authors:  Massimo Libra; Grazia Malaponte; Patrick M Navolanic; Pietro Gangemi; Valentina Bevelacqua; Lidia Proietti; Bibiana Bruni; Franca Stivala; Maria C Mazzarino; Salvatore Travali; James A McCubrey
Journal:  Cell Cycle       Date:  2005-10-13       Impact factor: 4.534

8.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors:  Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

9.  JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained.

Authors:  D P Steensma; R F McClure; J E Karp; A Tefferi; T L Lasho; H L Powell; G W DeWald; S H Kaufmann
Journal:  Leukemia       Date:  2006-06       Impact factor: 11.528

10.  Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation.

Authors:  Mamta Gupta; Jing Jing Han; Mary Stenson; Matthew Maurer; Linda Wellik; Guangzhen Hu; Steve Ziesmer; Ahmet Dogan; Thomas E Witzig
Journal:  Blood       Date:  2012-02-08       Impact factor: 22.113
View more
  4 in total

1.  Coexistence of gain-of-function JAK2 germ line mutations with JAK2V617F in polycythemia vera.

Authors:  Lucie Lanikova; Olga Babosova; Sabina Swierczek; Linghua Wang; David A Wheeler; Vladimir Divoky; Vladimir Korinek; Josef T Prchal
Journal:  Blood       Date:  2016-09-19       Impact factor: 22.113

2.  Synthetic Lethal Screen Demonstrates That a JAK2 Inhibitor Suppresses a BCL6-dependent IL10RA/JAK2/STAT3 Pathway in High Grade B-cell Lymphoma.

Authors:  Daniel Beck; Jenny Zobel; Ruth Barber; Sian Evans; Larissa Lezina; Rebecca L Allchin; Matthew Blades; Richard Elliott; Christopher J Lord; Alan Ashworth; Andrew C G Porter; Simon D Wagner
Journal:  J Biol Chem       Date:  2016-06-06       Impact factor: 5.157

3.  A novel missense (M206K) STAT3 mutation in diffuse large B cell lymphoma deregulates STAT3 signaling.

Authors:  Guangzhen Hu; Thomas E Witzig; Mamta Gupta
Journal:  PLoS One       Date:  2013-07-04       Impact factor: 3.240

4.  Loss of function mutations in PTPN6 promote STAT3 deregulation via JAK3 kinase in diffuse large B-cell lymphoma.

Authors:  Christos Demosthenous; Jing Jing Han; Guangzhen Hu; Mary Stenson; Mamta Gupta
Journal:  Oncotarget       Date:  2015-12-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.